United States Plague Market Size & Outlook, 2026-2034
United States Plague Market Insights
- As per Reed Intelligence insights, the United States Plague Market stood at USD 350.78 Million in 2025 and is anticipated to grow to USD 773.13 Million by 2034.
- The United States market is expected to advance at a CAGR of 9.16% from 2026 through 2034.
- In 2025, Diagnostics accounted for the highest share of the Product market size.
- During the forecast period, Vaccines is set to register the highest growth, making it the most lucrative Product segment.
![United States Plague Market Size, Share & Growth Report By [2034]](https://reedintelligence.com/uploads/charts/united-states-plague-market-united-states-product-135357.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2025, United States held 29.73% of the global Plague Market size.
- By 2034, United States is anticipated to capture the largest share of the global Plague Market.
- In North America, United States is expected to lead the regional Plague Market size by 2034.
- United States will remain the fastest-growing market in North America, reaching USD 772 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 350.78 Million |
| Market Size In 2034 | USD 773.13 Million |
| Largest segment | Diagnostics |
| Units | Revenue in USD Million |
| CAGR | 9.16% (2026-2034) |
| Segmnetation Covered | |
| Product |
|
| End-Use |
|
| Distribution Channel |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Plague Market Product 2026-2034 (USD Million)
| Product | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | XX.x | XX.x | XX.x | 188.58 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vaccines | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Therapeutics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Plague Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public Health Laboratories | XX.x | XX.x | XX.x | 174.06 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hospitals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Research Institutes | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United States Plague Market Distribution Channel 2026-2034 (USD Million)
| Distribution Channel | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct Procurement | XX.x | XX.x | XX.x | 179.71 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medical Distributors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Online Platforms | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
